This database contains 6 studies, archived under the term: "aMCI"
Effects of multicomponent exercise on cognitive function in older adults with amnestic mild cognitive impairment: a randomized controlled trial
Suzuki, Takao,
Shimada, Hiroyuki,
Makizako, Hyuma,
Doi, Takehiko,
Yoshida, Daisuke,
Tsutsumimoto, Kota,
Anan, Yuya,
Uemura, Kazuki,
Lee, Sangyoon,
Park, Hyuntae
Background: To examine the effects of a multicomponent exercise program on the cognitive function of older adults with amnestic mild cognitive impairment (aMCI).; Design: Twelve months, randomized controlled trial;; Setting: Community center in Japan;; Participants: Fifty older adults (27 men) with aMCI ranging in age from 65 to 93 years (mean age, 75 years);; Intervention: […]
Does a multicomponent exercise program improve dual-task performance in amnestic mild cognitive impairment? A randomized controlled trial
Makizako, Hyuma,
Doi, Takehiko,
Shimada, Hiroyuki,
Yoshida, Daisuke,
Tsutsumimoto, Kota,
Uemura, Kazuki,
Suzuki, Takao
Background and Aims: There has been much interest in exercise interventions as a primary behavioral prevention strategy against cognitive decline. The aim of this study was to evaluate the effect of a multicomponent exercise program on physical and dual-task performances in community-dwelling older adults with amnestic mild cognitive impairment (aMCI).; Methods: Fifty older adults (23 […]
Mnemonic strategy training improves memory for object location associations in both healthy elderly and patients with amnestic mild cognitive impairment: a randomized, single-blind study
Hampstead, Benjamin M.,
Sathian, Krish,
Phillips, Pamela A.,
Amaraneni, Akshay,
Delaune, William R.,
Stringer, Anthony Y.
Objective: To evaluate the efficacy of mnemonic strategy training versus a matched-exposure control condition and to examine the relationship between training-related gains, neuropsychological abilities, and medial temporal lobe volumetrics in patients with amnestic mild cognitive impairment (aMCI) and age-matched healthy controls.; Method: Twenty-three of 45 screened healthy controls and 29 of 42 screened patients with […]
Donepezil delays progression to AD in MCI subjects with depressive symptoms
Lu, P. H.,
Edland, S. D.,
Teng, E.,
Tingus, K.,
Petersen, R. C.,
Cummings, J. L.
Objective: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship.; Methods: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer’s Disease Cooperative Study drug trial […]
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study
Doody, Rachelle S.,
Ferris, Steven,
Salloway, Stephen,
Yijun, Sun,
Goldman, Robert,
Yikang, Xu,
Gao, Jeff,
Murthy, Anita K.
Following a 48-week, double-blind, randomized, placebo-controlled trial of donepezil in 821 patients with amnestic mild cognitive impairment (aMCI), safety and tolerability of donepezil (10 mg) were further evaluated in a 28-week extension study. Of 499 participants who completed the double-blind phase, 145 enrolled in the open-label study. Adverse events (AEs) were recorded throughout. Overall, 57.4% […]